BetterLife Pharma Business Summary

BetterLife Pharma Inc. (BETRF) is a clinical-stage biopharmaceutical company specializing in the development and commercialization of patented, non-hallucinogenic neuroplastogens for the treatment of mental health and neurological disorders. The company’s business model is centered on a proprietary drug discovery and development pipeline, primarily generating value through the advancement of its lead asset, BETR-001 (a non-controlled LSD derivative), and BETR-002 (a honokiol-based anxiolytic). BetterLife operates through two primary segments: Neuro-Psychiatric Therapeutics, focusing on major depressive disorder and anxiety, and Antiviral/Interferon Technologies, which includes MM-001 for HPV-induced cervical neoplasia and MM-003 for respiratory infections. Positioned against direct competitors such as Cybin Inc., Compass Pathways, MindMed, and PharmAla Biotech, BetterLife differentiates itself by focusing exclusively on non-hallucinogenic compounds that allow for self-administration, thereby bypassing the intensive clinical supervision and regulatory hurdles associated with traditional psychedelic-assisted therapies. The leadership team is anchored by Founder, CEO, and Chairman Dr. Ahmad Doroudian, a seasoned pharmaceutical executive who previously founded and led Merus Labs (acquired by Norgine). He is supported by Chief Operating Officer Dr. Hooshmand Sheshbaradaran, who brings over 30 years of global drug development experience from senior roles at Pharmacia/Pfizer and Roche, and CFO Moira Ong, who previously managed financial reporting and M&A integrations at Merus Labs. The company’s strategic direction is further bolstered by a board that includes major investor Dr. Steven Sangha and veteran director Dr. Wolfgang Renz, alongside a high-profile advisory group featuring Douglas Drysdale (CEO of Cybin) and Daniel Carcillo (Founder of Wesana Health). This pedigree of leadership combines deep expertise in specialty pharmaceutical acquisitions with advanced neuro-pharmacological research to drive the company’s IND-enabling studies and clinical trial progression.